Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

Delayed Quote. Delayed  - 08/28 10:26:04 am
19470 ILa   -0.51%
08/25 TEVA PHARMACEUT : US board invalidates Copaxone double-dose patents
08/24 TEVA PHARMACEUT : Confirms PTAB’s Decisions on Two Patents in ..
08/22 TEVA PHARMACEUT : ex-dividend day for interim dividend
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Illumina: Teva Pharmaceutical Exclusive Distributor of Verifi Test in Israel

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/01/2013 | 01:27pm CEST
   By Melodie Warner 
 

Illumina Inc. (>> Illumina, Inc.) said Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)) will be the exclusive distributor of the verifi prenatal test in Israel under a five-year agreement.

Financial terms weren't disclosed.

Illumina paid $350 million in February to buy Verinata Health Inc., which gave it access to Verinata's verifi prenatal test, the broadest non-invasive prenatal test currently available for high-risk pregnancies.

The company said the MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality.

The MOR Institute will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata.

Illumina said the patient registry developed through this collaboration will be the largest and most extensive of its kind.

Illumina shares closed Friday at $74.84 and were inactive premarket. The stock is up 35% this year.

Write to Melodie Warner at melodie.warner@dowjones.com

Stocks mentioned in the article : Illumina, Inc., Teva Pharmaceutical Industries Ltd (ADR)
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
08/25 TEVA PHARMACEUTICAL INDUSTRIES : US board invalidates Copaxone double-dose paten..
08/25 TEVA PHARMACEUTICAL INDUSTRIES : European Commission Grants Marketing Authorizat..
08/24 TEVA PHARMACEUTICAL INDUSTRIES : Confirms PTAB’s Decisions on Two Patents ..
08/22 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : ex-dividend day for interim dividend
08/18 TEVA PHARMACEUTICAL INDUSTRIES : Announces Launch of Generic Gleevec® Tablets in..
08/18 TEVA PHARMACEUTICAL INDUSTRIES : Patent Issued for Formulations of albu-BChE, Pr..
08/18 TEVA PHARMACEUTICAL INDUSTRIES : severe eosinophilic asthma drug Cinqaero wins E..
08/18 TEVA PHARMACEUTICAL INDUSTRIES : European Commission Grants Marketing Authorizat..
08/11 TEVA PHARMACEUTICAL INDUSTRIES : Announces Acquisition of Anda Inc.
08/11 TEVA PHARMACEUTICAL INDUSTRIES : Researchers Submit Patent Application, "Process..
More news
Sector news : Pharmaceuticals - NEC
08/27 Stada shareholder AOC pushes through board reshuffle
08/27 ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26 MUDDY WATERS SAYS ST. JUDE SHARES CO : Cnbc
08/26DJALERE : Sues Abbott to Force Merger -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/26 BIOTECH FORUM DAILY DIGEST : Clinton Takes A Swipe At Biotech, Revisiting The Bu..
08/26 A COMPREHENSIVE LOOK AT DIVIDEND GRO : Part 2
08/26 What's Going On At Mylan?
08/25 Teva Holds Cracking Door On Copaxone Generics
08/25 Shocked! Mylan, Biotechs Swoon After Hillary's Statement
Advertisement
Financials ($)
Sales 2016 23 091 M
EBIT 2016 7 748 M
Net income 2016 4 717 M
Debt 2016 25 666 M
Yield 2016 2,24%
P/E ratio 2016 11,88
P/E ratio 2017 9,81
EV / Sales 2016 3,40x
EV / Sales 2017 2,83x
Capitalization 52 759 M
More Financials
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 68,0 $
Spread / Average Target 31%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Erez Vigodman President, Chief Executive Officer & Director
Yitzhak Peterburg Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL IN..-23.10%52 759
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-11.47%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-9.62%210 234
ASTRAZENECA PLC7.33%173 797
More Results